Table 2. Relationship between GRHL2 expression level and clinicopathological variables in colorectal cancer patients.
| Variables | Subgroup | GRHL2 expression | P value | ||
|---|---|---|---|---|---|
| Total | Negative | Positive | |||
| Gender | Male | 40 | 15 (37.5%) | 25 (62.5%) | 0.824 |
| Female | 35 | 14 (40.0%) | 21 (60.0%) | ||
| Age (years) | <60 | 32 | 12 (37.5%) | 20 (62.5%) | 0.858 |
| ≥60 | 43 | 17 (39.5%) | 26 (60.5%) | ||
| Histology | Tubular | 60 | 23 (38.3%) | 37 (61.7%) | 0.906 |
| Mucinous | 15 | 6 (40.0%) | 9 (60.0%) | ||
| Site | Rectum and sigmoid | 49 | 19 (38.8%) | 30 (61.2%) | 0.723 |
| Right colon | 18 | 6 (33.3%) | 12 (66.7%) | ||
| Left colon | 8 | 4 (50.0%) | 4 (50.0%) | ||
| Size | <3 cm | 25 | 14 (56.0%) | 11 (44.0%) | 0.029 |
| ≥3 cm | 50 | 15 (30.0%) | 35 (70.0%) | ||
| TNM stage | I+II | 30 | 16 (53.3%) | 14 (46.7%) | 0.033 |
| III+IV | 45 | 13 (28.9%) | 32 (71.1%) | ||
| Ki-67 | Low | 31 | 17 (54.8%) | 14 (45.2%) | 0.016 |
| High | 44 | 12 (27.3%) | 32 (72.7%) | ||
*
Statistically significant